A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.Jing‐Jing Li, Jieer Ying, Qi Xu et al.|Journal of Clinical Oncology|2022Cited by 7